Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

38 results about "Symptom Cluster" patented technology

The typical symptoms of cluster headache include grouped occurrence and recurrence (cluster) of headache attack, severe unilateral orbital, supraorbital and/or temporal pain.

Antagonist Antibodies Directed Against Calcitonin Gene-Related Peptide and Methods Using Same

The invention features methods for preventing or treating CGRP associated disorders such as vasomotor symptoms and / or headaches (e.g., migraine, cluster headache, and tension headache) by administering an anti-CGRP antagonist antibody. Compositions for use in the disclosed methods are also provided. Antagonist antibody G1 and antibodies derived from G1 directed to CGRP are also described.
Owner:TEVA PHARMACEUTICALS INTERNATIONAL GMBH

Oxygen inhalation device for treating cluster headache

The invention relates to the field of medical instruments, in particular to an oxygen inhalation device for treating cluster headache, which comprises a shell and a controller, the top of the shell is communicated with an air outlet pipe, and one end, far away from the shell, of the air outlet pipe is communicated with a breathing mask; a purification mechanism, an amplification mechanism and a linkage mechanism are arranged in the shell, and the purification mechanism is used for separating and purifying oxygen from ambient air; the amplifying mechanism is used for pressurizing the oxygen output by the purifying mechanism and outputting the oxygen to the breathing mask. The linkage mechanism is used for converting the switching power of the amplifying mechanism into movement for driving the purification mechanism to periodically switch, so that the switching period of the purification mechanism is synchronous with the gas supply period of the amplifying mechanism, and the adsorption and desorption flow switching of the purification mechanism is realized. Cooperative utilization of energy is achieved through the linkage mechanism, and the energy efficiency of equipment is improved; the amplification mechanism drives the purification mechanism to periodically switch, so that the secondary conversion loss of energy is reduced; the dependence on external power energy is reduced, the economic pressure can be reduced, and the treatment sustainability is improved.
Owner:TIANJIN HUANHU HOSPITAL (TIANJIN NEUROSURGICAL INSTITUTE TIANJIN NEUROLOGICAL DISEASE CENTER HOSPITAL)

Compositions comprising elismetrep for treating or preventing migraine or pain

The present invention relates to compositions comprising 4-({(4-cyclopropylisoquinolin-3-yl)[4- (trifluoromethoxy)benzyl] amino }sulfonyl)benzoic acid (elismetrep; MT-8554), or a pharmaceutically acceptable salt thereof, for treating or preventing pain, particularly migraine or a trigeminal pain disease or condition such as medication overuse headache, cluster headache, general headache, trigeminal neuralgia, trigeminal neuropathy, trigeminal autonomic cephalalgia, orofacial pain, and dental pain.
Owner:KALLYOPE INC

Pharmaceutical composition for treating migraine

The present application relates to a method of treating migraine or cluster headache in a human patient, said method comprising administering subcutaneously composition comprising sumatriptan or its pharmaceutically acceptable salt, in an amount equivalent to 3 mg sumatriptan base.
Owner:TONIX MEDICINES INC

Phenethylamines and methods of preparation thereof

The present disclosure relates to compounds of Formula I that exhibit 5-HT2A receptor agonist activity and low 5HT2B receptor agonist activity or deemed 5HT2B receptor agonist inactivity. In at least some cases, such compounds show selectivity for the 5-HT2A receptor over the 5-HT2C receptor. As contemplated herein, phenethylamines may be used for the treatment of neuropsychiatric, neurodegenerative, neuroinflammatory and pain disorders including depression, drug (e.g. tobacco, opiate, and cocaine) addiction, alcoholism, post-traumatic stress disorder (PTSD), and neuropathic pain syndromes including cluster headaches and chemotherapy induced peripheral neuropathy.
Owner:BRIGHT MINDS BIOSCIENCES INC

Pharmaceutical compounds, pharmaceutical compositions, and methods of treating depression and other disorders

In some aspects, pharmaceutical compounds are disclosed which may be useful for treating anxiety and / or other disorders. In another aspect, a pharmaceutical composition includes a therapeutically effective amount of the compound(s) and a pharmaceutically acceptable vehicle therefor. In yet another aspect, a method of treating anxiety, depression, obsessive-compulsive disorder, tobacco addiction, alcohol addiction, cocaine addiction, headache, cluster headache, or cancer-related or other end-of-life psychological distress involves administering the pharmaceutical composition to an individual in need thereof.
Owner:MIRALOGX LLC

Anti-human PAC1 antibodies or antigen-binding fragments thereof and methods of use thereof for inhibiting vasodilation and ameliorating a headache condition

The present invention relates to neutralizing antibodies of the human pituitary adenylate cyclase activating polypeptide type I receptor (PAC1) and pharmaceutical compositions comprising such antibodies. Methods of treating or preventing headache conditions, such as migraine and cluster headache, using the neutralizing antibodies are also described.
Owner:AMGEN INC

AI-assisted clinical decision support and automated treatment workflow system with bidirectional provider collaboration and multi-symptom processing

A system for AI-assisted clinical decision support with multi-symptom processing architecture, bidirectional provider-AI collaboration, and universal integration capabilities. The system implements a symptom clustering algorithm that identifies relationships between reported symptoms through vector representation in a multi-dimensional clinical feature space, enabling parallel processing of multiple complaint clusters through separate but interconnected computational pathways. A bidirectional provider-AI collaboration system implements verification interfaces with confidence indicators and provenance tracking, enabling continuous refinement based on provider feedback. A dynamic knowledge graph integrates multiple knowledge sources with relationship weight calculation algorithms. A real-time interactive refinement interface implements tristate finding representation with impact visualization and instantaneous probability recalculation. A universal adapter pattern enables seamless integration with external healthcare systems through adaptive protocols and bidirectional semantic mapping. This technical architecture improves computational efficiency, diagnostic accuracy, and system interoperability while maintaining appropriate provider oversight.
Owner:ISBELL SCOTT ANTHONY

Amino acid and carbohydrate psilocin derivatives

This disclosure relates to heterocyclic compounds of Formula (I) as well as the preparation and use thereof. As contemplated herein, heterocyclic compounds of Formula (I) can be any one of a carbohydrate conjugate and an amino acid conjugate. The heterocyclic compounds of Formula (I) may be used for the treatment of neuropsychiatric, and neurodegenerative, neuroinflammatory and pain disorders including depression, as well as tobacco, opiate, and cocaine addiction, alcoholism, post-traumatic stress disorder (PTSD), and pain syndromes including cluster headaches and chemotherapy induced peripheral neuropathy.
Owner:BIONXT SOLUTIONS INC

Treatment of headache disorders with NK3 modulators

PendingUS20250270330A1Nervous disorderAntibody mimetics/scaffoldsOrofacial painAnalgesic rebound headache
The present invention relates to a method for treating or preventing headache disorders selected from the group consisting of migraine, medication overuse headache, cluster headache, general headache, trigeminal neuralgia, and orofacial pain, comprising administering a therapeutically effective amount of a therapeutic agent that modulates activity of a Neurokinin Receptor 3 (“NK3”) protein or modulates expression of a TACR3 gene.
Owner:KALLYOPE INC

Lipid prodrugs of bromoerguramide and uses thereof

PendingCN122341602AHeadachesCluster headache
This article discloses a lipid prodrug of bromo-lysergic acid diethylamide (2-bromo-LSD) (2-bromo-lysergic acid diethylamide), which achieves improved pharmacokinetic properties and allows for easier long-term administration to patients. The disclosed lipid prodrug is indicated for the treatment of cluster headaches and mood disorders in human subjects.
Owner:HARBOR THERAPY CORP

Methods of treating migraine

The present application relates to a method of reducing a need of rescue medication and / or a need of more than one dose of migraine medication in a patient suffering from cephalic pain, including migraine, cluster headache, episodic migraine, or rapid escalating migraine. In some embodiments, the method includes administering intranasally a composition comprising sumatriptan, or a physiologically-acceptable salt or a solvate thereof, and an alkyl glycoside or a saccharide alkyl ester.
Owner:TONIX MEDICINES INC

Method and system for predicting symptom cluster trajectory after colorectal cancer surgery based on multi-source data

ActiveCN121034640BMathematical modelsMedical data miningPostoperative managementAlgorithm
The application discloses a postoperative symptom group trajectory prediction method and system based on multi-source data, relates to the technical field of postoperative management of colorectal cancer, and comprises the following steps: obtaining a unique identity identifier and static physiological characteristics of a target patient, querying a historical evolution trend and a historical intervention trajectory of a postoperative symptom group of the target patient according to the unique identity identifier; obtaining a target intervention measure; and inputting the static physiological characteristics, the historical evolution trend, the historical intervention trajectory and the target intervention measure into a pre-trained trajectory prediction model to generate an expected evolution trend of a target symptom, so that a technical transformation from single-time risk prediction to continuous trajectory prediction for auxiliary decision-making is realized.
Owner:SICHUAN ACADEMY OF MEDICAL SCI SICHUAN PROVINCIAL PEOPLES HOSPITAL

Method for transnasal delivery of cannabidiol and other therapeutic treatments

A novel method for treating one or more of self-reported or clinically-diagnosed depression, substandard sleep quality, appetite control issues, social anxiety, general anxiety, PTSD, traumatic memory-related stress, cluster headaches, intractable phantom-limb pain (PLP), chronic pain, and / or obsessive compulsive disorders (OCD) may include transnasally delivering one or more of CBD, Dimethyltryptamine (DMT), Psilocybin, Δ8-tetrahydrocannabinol, and Δ9-tetrahydrocannabinol, or any effective variant or derivative thereof, to the sphenopalatine ganglion of a patient. This method of delivery will provide effective treatment including at least alleviating one or more symptoms of one or more of self-reported anxiety, self-reported depression, and / or self-reported substandard sleep quality, with an effective dosage amount that is administered differently than prior CBD treatments.
Owner:XIA TIAN

Colorectal cancer postoperative symptom group trajectory prediction method and system based on multi-source data

ActiveCN121034640AMathematical modelsMedical data miningPostoperative managementAlgorithm
The invention discloses a colorectal cancer postoperative symptom group trajectory prediction method and system based on multi-source data, and relates to the technical field of colorectal cancer postoperative management, and the method comprises the steps: obtaining a unique identity label and a static physiological feature of a target patient, querying a historical evolution trend and a historical intervention track of the postoperative symptom group of the target patient according to the unique identity identifier; and acquiring a target intervention measure, and inputting the static physiological features, the historical evolution trend, the historical intervention trajectory and the target intervention measure into a pre-trained trajectory prediction model to generate an expected evolution trend of the target symptom, thereby realizing technical transformation of auxiliary decision making from single-moment risk prediction to continuous trajectory prediction.
Owner:SICHUAN ACADEMY OF MEDICAL SCI SICHUAN PROVINCIAL PEOPLES HOSPITAL

Multi-level traditional Chinese medicine ancient book symptom standardized processing method

The invention belongs to the technical field of natural language processing, and discloses a multilevel traditional Chinese medicine ancient book symptom standardization processing method, which comprises the following steps: obtaining traditional Chinese medicine ancient book texts to extract initial symptom expression; splitting the composite symptom by adopting a mode of combining a preset rule engine and a large language model to obtain a single symptom expression; calculating the multi-dimensional similarity of the single symptom expression based on a preset standard symptom word bank, carrying out weighted fusion to obtain a comprehensive similarity score, and if the comprehensive similarity score is not lower than a preset threshold value, determining a corresponding standard symptom from the standard symptom word bank as a standardized expression of the initial symptom expression; and otherwise, clustering the single symptom expressions, and classifying the single symptom expressions into a symptom cluster to serve as standardized expressions of the single symptom expressions. According to the method, all the symptom information extracted from the ancient books is ensured to be effectively processed and classified, and a real complete ancient symptom knowledge system is constructed.
Owner:CHENGDU UNIV OF TRADITIONAL CHINESE MEDICINE

Treatment of headache disorders using NK3 modulators

The present invention relates to a method for treating or preventing a headache disorder selected from the group consisting of migraine, headache due to drug overuse, cluster headache, general headache, trigeminal neuralgia, and oral and facial pain, comprising administering a therapeutically effective amount of a therapeutic agent that modulates the activity of the neurokinin receptor 3 ('NK3') protein or modulates the expression of the TACR3 gene.
Owner:KALLYOPE INC

Therapeutic composition of intranasal lidocaine

To provide formulations for providing pain relief in humans and animals by administering a preservative-free intranasal dose of a local anesthetic formulation for the treatment of tri-geminal neuralgia, facial neuropathic pain, facial cancer induced neuropathic pain, migraine pain, and cluster headache pain.SOLUTION: A nasal spray formulation comprises from about 5% to about 30% w / v of a locally active sodium channel blocker, from about 0.25% to about 5% w / v of a buffering agent, and from about 5% to about 99% w / v of a pharmaceutically acceptable carrier for nasal administration. The nasal spray formulation is preferably contained in a mechanical multi-dose pump which sprays a unit dose of the nasal spray formulation with a wide plume and small droplet size, and the unit dose is administered by actuating the mechanical multi-dose spray pump device and spraying a certain amount of the nasal spray formulation into each nostril of a human subject. Preferably, the nasal spray formulation does not include a preservative.SELECTED DRAWING: None
Owner:GRACE THERAPEUTICS LLC

Phenethylamine and its preparation method

This disclosure relates to 5-HT 2A It exhibits receptor agonist activity and inhibits 5-HT 2B Low receptor agonist activity or 5-HT 2B The present invention relates to compounds represented by formula I, which are considered to be inactive 5-HT receptor agonists. 2C 5-HT receptors 2A As contemplated herein, phenethylamines may be used for the treatment of neuropsychiatric, neurodegenerative, neuroinflammatory and pain disorders, including depression, drug (e.g., tobacco, opiate and cocaine) addiction, alcoholism, post-traumatic stress disorder (PTSD) and neuropathic pain syndromes, including cluster headache and chemotherapy-induced peripheral neuropathy. [Formula 1] TIFF2025503579000028.tif57161
Owner:BRIGHT MINDS BIOSCIENCES INC

Pharmaceutical composition for treating migraine

The present application relates to a method of treating migraine or cluster headache in a human patient, said method comprising administering subcutaneously composition comprising sumatriptan or its pharmaceutically acceptable salt, in an amount equivalent to 3 mg sumatriptan base.
Owner:TONIX MEDICINES INC